U.S. markets closed

Cidara Therapeutics, Inc. (CDTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.4444-0.0305 (-6.42%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close0.4749
Bid0.4300 x 1200
Ask0.4999 x 1800
Day's Range0.4355 - 0.4914
52 Week Range0.4120 - 2.3900
Avg. Volume272,814
Market Cap30.686M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-0.7370
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CDTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cidara Therapeutics, Inc.
    Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Benzinga

    Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

    U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed that the application filing of lead antifungal drug rezafungin as a potential first-line treatment for candidemia and invasive candidiasis remains on track for mid-2022, which HC Wainwright takes to mean as late as August. HC Wainwright lowered the price target to $6 from $7.50, citing the challenging capi

  • Zacks

    Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

    Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

    SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline. “We continue to advance our pipeline of Cloudbreak DFC product candidates,” said Jeffrey Stein, Ph.D., president and chief exe